Cardiometabolic Disease
Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: Results from a randomized trial
Scientific Publications & Presentations
Built on decades of scientific leadership, Ionis continues to advance the understanding of disease through groundbreaking research and innovation. Explore select publications across our therapeutic areas and technologies to better understand the science behind our medicines and pipeline.
Showing 13-23 out of 23 results
Cardiometabolic Disease
Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants
Other Medicines
Donidalorsen Data Presented at the American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress
Cardiometabolic Disease
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America
Other Medicines
Efficacy and Safety of Donidalorsen for Hereditary Angioedema
Cardiometabolic Disease
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Cardiometabolic Disease
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Cardiometabolic Disease
Olezarsen Data Presented at the 2024 American College of Cardiology Annual Meeting
Other Medicines
Inhibition of Prekallikrein for Hereditary Angioedema
Cardiometabolic Disease
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
Cardiometabolic Disease
Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study